Expectations trend
FY2028 · fiscal year ending 2028-03-31 · fmp
PetMed Express Inc (PETS)
NASDAQHealth CareSpecialty RetailSnapshot 2026-11-04
$1.24+3.33%
Close 2026-11-04 · 1-day change
NASDAQHealth CareSpecialty RetailSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for PETS yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Operating cash flow improves to no worse than negative $4.7M by 2026-Q4 | PetMed Express is cutting losses, improving operating income from negative $34.1M to negative $5.7M by 2026-Q4. | Broken | Operating cash flow worse than negative $4.7M in 2026-Q4 | Cash from operations: $-7.687M FY2027-Q1; GAAP. Published target: >= -4.7 million USD. The stored target says 2026-Q4; this source reports FY2027-Q1. Fiscal/calendar alignment needs review. Aug 13, 2026-7,687,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-03-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk turnaround case, not a proven durable compounder. The multi-year view remains intact, but evidence of progress is mixed and confidence is medium.
PETS is described as cheap versus peers, while the valuation model has low confidence and the expectations gap is negative. The evidence does not show that the low valuation reflects a dependable recovery; repeated misses and weak sales remain important concerns.
Near term, earnings risk is elevated after consecutive misses, and a guidance cut could add pressure to the business outlook. Recent results show sales falling while losses narrowed, but management's cost work and expansion into B2B and pharmacy services have not yet produced revenue growth. CEO and director transitions add uncertainty.
Over the next few quarters, the thesis hinges on whether cost reductions can keep improving losses while sales stabilize. Further guidance cuts or weaker employment data would be unfavorable; continued strength from the sector bellwether WRBY could support sector momentum. The real estate sale-leaseback remains a watch item, with little evidence provided on its progress.
For the 1-3 year view, PETS remains an unproven turnaround with some improvement in losses but a weak revenue trajectory and elevated execution risk. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Net income improves to no worse than negative $4.1M by 2026-Q4 | The company aims to reduce net losses from negative $34.2M to negative $4.1M in the same period. | Broken | Net income worse than negative $4.1M in 2026-Q4 | Net income: $-6.145M FY2027-Q1; GAAP. Published target: >= -4.1 million USD. The stored target says 2026-Q4; this source reports FY2027-Q1. Fiscal/calendar alignment needs review. Aug 13, 2026-6,145,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Operating income improves to no worse than negative $5.7M by 2026-Q4 | PetMed Express is cutting losses, improving operating income from negative $34.1M to negative $5.7M by 2026-Q4. | Broken | Operating income worse than negative $5.7M in 2026-Q4 | Operating income: $-6.232M FY2027-Q1; GAAP. Published target: >= -5.7 million USD. The stored target says 2026-Q4; this source reports FY2027-Q1. Fiscal/calendar alignment needs review. Aug 13, 2026-6,232,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue near $95M in 2025 and not declining more than 12% next year | Revenue is expected near $95M in 2025, showing some stability. | Broken | Revenue falls below $83.6M in FY26 | Revenue: $41.015M FY2027-Q1; GAAP. Published target: >= 83.6 million USD (12% decline from $95M). Annual target cannot be compared with a quarterly or TTM observation. Aug 13, 202641,015,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.09 → $-0.35 · observed estimates
$0.18B → $0.15B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-07-25 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-07-26 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-07-27 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-07-28 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-07-29 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-07-30 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-07-31 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-08-01 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-08-02 | $0.09 | $184,402,000 | 1 / 1 |
| 2026-08-03 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-08-04 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-08-05 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-08-06 | $0.09 | $184,402,000 | 1 / 1 |
| 2026-08-07 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-08-08 | $0.09 | $184,402,000 | 1 / 1 |
| 2026-08-09 | $0.09 | $184,402,000 | 1 / 1 |
| 2026-08-10 | $0.09 | $184,402,000 | 1 / 1 |
| 2026-08-12 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-08-13 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-08-14 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-08-15 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-08-16 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-08-17 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-08-18 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-08-19 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-08-20 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-08-21 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-08-22 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-08-23 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-08-24 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-08-25 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-08-26 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-08-27 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-08-28 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-08-29 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-08-30 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-08-31 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-09-01 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-09-02 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-09-03 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-09-04 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-09-05 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-09-06 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-09-07 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-09-08 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-09-09 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-09-10 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-09-11 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-09-12 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-09-13 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-09-14 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-09-15 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-09-16 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-09-17 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-09-18 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-09-19 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-09-20 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-09-21 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-09-22 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-09-23 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-09-24 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-09-25 | $0.09 | $184,402,002 | 1 / 1 |
| 2026-09-26 | $-0.35 | $152,498,768 | 1 / 1 |
| 2026-09-27 | $-0.35 | $152,498,768 | 1 / 1 |
| 2026-09-28 | $-0.35 | $152,498,768 | 1 / 1 |
| 2026-09-29 | $-0.35 | $152,498,768 | 1 / 1 |
| 2026-09-30 | $-0.35 | $152,498,768 | 1 / 1 |
| 2026-10-01 | $-0.35 | $152,498,768 | 1 / 1 |
| 2026-10-02 | $-0.35 | $152,498,768 | 1 / 1 |
| 2026-10-03 | $-0.35 | $152,498,768 | 1 / 1 |
| 2026-10-04 | $-0.35 | $152,498,768 | 1 / 1 |
| 2026-10-05 | $-0.35 | $152,498,768 | 1 / 1 |
| 2026-10-06 | $-0.35 | $152,498,768 | 1 / 1 |
| 2026-10-07 | $-0.35 | $152,498,768 | 1 / 1 |
| 2026-10-08 | $-0.35 | $152,498,768 | 1 / 1 |
| 2026-10-09 | $-0.35 | $152,498,768 | 1 / 1 |
| 2026-10-10 | $-0.35 | $152,498,768 | 1 / 1 |
| 2026-10-11 | $-0.35 | $152,498,768 | 1 / 1 |
| 2026-10-12 | $-0.35 | $152,498,768 | 1 / 1 |
| 2026-10-13 | $-0.35 | $152,498,768 | 1 / 1 |
| 2026-10-14 | $-0.35 | $152,498,768 | 1 / 1 |
| 2026-10-15 | $-0.35 | $152,498,768 | 1 / 1 |
| 2026-10-16 | $-0.35 | $152,498,768 | 1 / 1 |
| 2026-10-17 | $-0.35 | $152,498,768 | 1 / 1 |
| 2026-10-18 | $-0.35 | $152,498,768 | 1 / 1 |
| 2026-10-19 | $-0.35 | $152,498,768 | 1 / 1 |
| 2026-10-20 | $-0.35 | $152,498,768 | 1 / 1 |
| 2026-10-21 | $-0.35 | $152,498,768 | 1 / 1 |
| 2026-10-22 | $-0.35 | $152,498,768 | 1 / 1 |
| 2026-10-23 | $-0.35 | $152,498,768 | 1 / 1 |
| 2026-10-24 | $-0.35 | $152,498,768 | 1 / 1 |
| 2026-10-25 | $-0.35 | $152,498,768 | 1 / 1 |
| 2026-10-26 | $-0.35 | $152,498,768 | 1 / 1 |
| 2026-10-27 | $-0.35 | $152,498,768 | 1 / 1 |
| 2026-10-28 | $-0.35 | $152,498,768 | 1 / 1 |
| 2026-10-29 | $-0.35 | $152,498,768 | 1 / 1 |
| 2026-10-30 | $-0.35 | $152,498,768 | 1 / 1 |
| 2026-10-31 | $-0.35 | $152,498,768 | 1 / 1 |
| 2026-11-01 | $-0.35 | $152,498,768 | 1 / 1 |
| 2026-11-02 | $-0.35 | $152,498,768 | 1 / 1 |
| 2026-11-03 | $-0.35 | $152,498,768 | 1 / 1 |
| 2026-11-04 | $-0.35 | $152,498,768 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 0 Buy / Strong Buy · 0 Hold · 1 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 10, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.